Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Semaglutide Muscle Loss: Why the Published Numbers Disagree
articleThere is no single semaglutide muscle loss figure. Four Tier 1 studies measured different populations, doses, and tissues, and the widely repeated percentages are back-calculations rather than stated trial results.
Retatrutide Muscle Mass Preservation: What the DEXA Data Shows
articleRetatrutide does not prevent lean mass loss, but the proportion lost is similar to other obesity treatments. Here is what the DEXA data shows, why the glucagon receptor is only a hypothesis, and what actually protects muscle.